CXCL10 (IP-10) and CCL2 (MCP-1) were both found to have significant associations with higher tumor burden in the E0771 ICI monotherapy study and the combined E0771 and 4T1 groups treated with anti-PD-1. Here, CXCL10 is linked to neoplasm.